Brief: Armata Pharma Announces Data From Phase 1B/2A Trial Of Inhaled AP-Pa02 In Patients With Cystic Fibrosis
06/03/2023 11:25
March 6 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA
FROM
PHASE 1B/2A SWARM-P.A. CLINICAL TRIAL OF INHALED AP-PA02 IN
PATIENTS WITH CYSTIC FIBROSIS
* ARMATA PHARMACEUTICALS INC - AP-PA02 IS WELL-TOLERATED AND
DATA
SUPPORTS PROGRESSION TO PHASE 2B
* ARMATA - ANNOUNCES FIRST SUBJECT DOSED IN PHASE 2
'TAILWIND'
CLINICAL TRIAL OF INHALED AP-PA02 IN PATIENTS WITH NON-CYSTIC
FIBROSIS BRONCHIECTASIS
Source text for Eikon: ID:nPn9hk1X7a
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles